All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Blinatumomab as last consolidation prior to allo-HSCT in pediatric and young adult patients with B-cell ALL
Bookmark this article
|
A single-center, retrospective analysis assessed the outcomes of 78 pediatric and young adult patients with B-ALL who were treated with blinatumomab, a bispecific T-cell engager, as last consolidation therapy prior to allo-HSCT at Bambino Gesù Children's Hospital, IT.1 Results from this analysis were published in Haematologica by Algeri et al.1 |
| Key learnings |
| At a median follow-up of 23.2 months, the 2-year DFS, OS, CIR, and cumulative incidence of NRM rates were 72.2%, 89.2%, 25.2%, and 2.6%, respectively. |
| There was a trend towards improved 2-year DFS (92.9% vs 68.5%; p = 0.18) and lower CIR (0% vs 29.9%; p = 0.05) in patients transplanted in CR1 vs CR2/CR3. |
| The cumulative incidence of Grade II–IV aGvHD and cGvHD were 12.8% and 13%, with a 2-year GRFS rate of 68.4%. There were no recorded cases of SOS or TMA. |
| Results from this analysis suggest that blinatumomab is well-tolerated and effective as a pre-transplant treatment for pediatric and young adult patients with B-ALL. |
Abbreviations: aGvHD, acute graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; B-ALL, B-cell acute lymphoblastic leukemia; cGvHD, CIR, cumulative incidence of relapse; chronic graft-versus-host disease; CR, complete remission; DFS, disease-free survival; GRFS, graft-versus-host disease-free relapse-free survival; NRM, non-relapse mortality; SOS, sinusoidal obstruction syndrome; TMA, transplant-associated microangiopathy.
- Algeri M, Massa M, Pagliara D, et al. Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation. Haematologica. 2024. Online ahead of print. DOI: 3324/haematol.2024.286350
Your opinion matters
6 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox